Troglitazone, a peroxisome proliferator-activated receptor &gamma; ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells

doi:10.3748/wjg.14.2168

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 14

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3536)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series.

Item

Count

PDF

327

HTML

2927

Figures (1-7)

282

Sum=3536

Apr 14, 2008 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Apr 14, 2008; 14(14): 2168-2173
Published online Apr 14, 2008. doi: 10.3748/wjg.14.2168

Full Size Figure Download Figure

Figure 7 Effect of troglitazone on the expression of Bax and survivin. Lane 1: Control cells; lane 2: 20 &mgr;mol/L troglitazone; lane 3: 30 &mgr;mol/L troglitazone.

Citation: Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, Yin ZF. Troglitazone, a peroxisome proliferator-activated receptor γ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol 2008; 14(14): 2168-2173
URL: https://www.wjgnet.com/1007-9327/full/v14/i14/2168.htm
DOI: https://dx.doi.org/10.3748/wjg.14.2168